GlaxoSmithKline Articles
Japan to cut premium for new drug development to 80% and long-listed brand prices 2.2%
11 January 2010
UK govt in talks with GlaxoSmithKline to offload swine flu vaccine stocks as pandemic fails to materialize
11 January 2010
Blockbuster status predicted for co-formulation of rilpivirine and Truvada with sales of over $2 billion in the HIV Drug Market by 2018
7 January 2010
Negative outcome in arbitration with Asahi will cost Actelion $91 million; and bad news emerges with insomnia drug
23 December 2009
Seattle Genetics in deal with GSK for ADC worth up to $402 million
22 December 2009
Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid
22 December 2009
Europe’s CHMP serves up negative opinion for Ark’s Cerepro and calls for ban on benfluorex drugs, but good news for B-MS, Sanofi, GSK, Novartis
21 December 2009
Stiefel and Ferring named in advertisements for breaches of the ABPI Code of Practice
21 December 2009
Japan’s Chuikyo to decide on drug pricing by year end, as EFPIA executive warns of drugmakers likely exodus
18 December 2009
UNITAID HIV patent pool could save over $1 billion a year, put pressure on AIDS drugmakers
17 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Nabi Biopharma gets $5 million milestone from GlaxoSmithKline on progressing vaccine candidates
10 December 2009
Drug candidates in pipeline offer potential for Parkinson's disease market, says Frost & Sullivan
9 December 2009
Generic erosion will bite into the acute coronary syndrome market, cutting sales nearly 10% from 2008 to 2018
8 December 2009
GSK completes buying stake in SA’s Aspen, upping this to 19%
2 December 2009
European Commission tops a billion euros invested in the fight against the global AIDS epidemic; clears new pandemic flu vaccine use
1 December 2009
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
26 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Meeting highlights from Europe’s CHMP November 16-19, 2009
23 November 2009
Patient power and the role of biotech in Europe
20 November 2009
US FDA advisory panel backs Pfizer’s Prevnar 13
20 November 2009
EFA highlights urgent need for change and comprehensive European strategy to fight COPD
19 November 2009
Scam artists in USA cash in on Swine flu, says Consumer Reports
18 November 2009
GSK and Nabi in deal for NicVAX, with upfront and potential payments of over $500 million
17 November 2009
Astex could earn $500 million from strategic drug discovery alliance with GlaxoSmithKline
13 November 2009
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
Biota acquires antibacterial assets of Prolysis and of MaxThera
12 November 2009
GlaxoSmithKline’s pandemic H1N1 vaccine cleared by US FDA; firm donates 50M doses to WHO
12 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
Johnson & Johnson to shed 6%-7% of jobs; confirms 2009 guidance
4 November 2009
HGSI and GSK post strong Ph III results with Benlysta in lupus
2 November 2009
Big Pharma concludes M&A is not the new R&D
30 October 2009
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
UK’s NICE backs GSK’s Hycamtin for cervical cancer and Lilly’s Efient for preventing blood clots
28 October 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
Middle Eastern pharmaceutical market gaining in importance
21 October 2009
US FDA clears two indications for Boehringer Ingelheim’s telmisartan and GSK’s Votrient for renal cancer
20 October 2009
Swine flu vaccine shortage likely in the USA
19 October 2009
GlaxoSmithKline in $680 million deal with Prosensa to fight Duchenne Muscular Dystrophy
14 October 2009
Plans for new UK govt/industry drug development campus unveiled
14 October 2009
GlaxoSmithKline withdraws European MA for nausea drug Zunrisa
14 October 2009
Switzerland orders H1N1 vaccines from GSK and Novartis
12 October 2009
Cancer drugs emerging as top driver of specialty drug spending
12 October 2009
USPTO’s rescinding of controversial patent regulations package welcomed by industry; boost for GSK
12 October 2009
EU Commissioner Kroes still gunning for Pharma
30 September 2009
“No Frills Drugs” push Pharma to look for a cure
30 September 2009
GSK in 1.5 billion-euro deal with Brazil for pneumococcal vaccine; first Cervarix death reported
29 September 2009
GSK withdraws regulatory filings for nausea drug Zunrisa/Rezonic; progresses deal with Ligand
29 September 2009
EMEA backs flu vaccines from GlaxoSmithKline and Novartis
25 September 2009
Will Swine Flu provide proving ground for vaccine adjuvants?
25 September 2009
BIO-Europe 2009: an opportunity to hunt for deals
25 September 2009
Amgen’s pipeline boosted by new denosumab data
23 September 2009
GlaxoSmithKline to limit CME funding in USA
22 September 2009
VEM agrees to sell Ratiopharm; large number of interested parties
19 September 2009
“Novartis aims big in COPD market,” say Zacks analysts
17 September 2009
US FDA approves vaccines for 2009 H1N1 influenza virus
16 September 2009
Changes predicted in renal cell carcinoma market leaders
15 September 2009
New report on UK’s Big Pharma highlights productivity crisis
8 September 2009
US FDA reviews supports GlaxoSmithKline’s Cervarix and Merck & Co’s Gardasil in males
7 September 2009
SkyePharma slumps on US delay for Flutiform
2 September 2009
Romania’s Pharma market set to grow at 9% CAGR
1 September 2009
Is GlaxoSmithKline eyeing a $4 billion bid for Human Genome?
26 August 2009
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
